pramipexole

(redirected from Sifrol)
Also found in: Dictionary.
Related to Sifrol: pramipexole, Madopar

pramipexole

 [pram″ĭ-pek´sōl]
a dopamine agonist used in the form of the dihydrochloride salt in treatment of parkinson's disease, administered orally.

pramipexole

/pram·i·pex·ole/ (pram″ĭ-pek´sōl) a dopamine agonist used in the form of the dihydrochloride salt as an antidyskinetic in the treatment of Parkinson's disease.

pramipexole

(prăm′ə-pĕk′sōl′)
n.
A dopamine agonist used in the treatment of Parkinson's disease.

pramipexole

an antiparkinson agent.
indication It is used to treat parkinsonism.
contraindication Known hypersensitivity prohibits its use.
adverse effects Life-threatening effects are hemolytic anemia, leukopenia, and agranulocytosis. Other adverse effects include psychosis, hallucination, depression, dizziness, constipation, impotence, and blurred vision. Common side effects include agitation, insomnia, nausea, anorexia, and orthostatic hypotension.

pramipexole

Mirapex® Neurology A dopamine antagonist used to manage Parkinson's disease Adverse effects Constipation, dry mouth, vision defects, insomnia
References in periodicals archive ?
Evaluate the impact of upcoming patent expiries for Flomax and Sifrol on the company's outlook
Table 22: Key products overview 78 Table 23: Spiriva: overview 79 Table 24: Spiriva: sales forecast ($m), 2008-14 80 Table 25: Micardis: overview 84 Table 26: Micardis franchise: sales forecast ($m), 2008-14 85 Table 27: Pradaxa: overview 88 Table 28: Pradaxa: sales forecast ($m), 2008-14 89 Table 29: Ondero: overview 92 Table 30: Ondero: sales forecast ($m), 2008-14 93 Table 31: Sifrol: overview 94 Table 32: Sifrol franchise: sales forecast ($m), 2008-14 95 Table 33: Flomax: overview 97 Table 34: Flomax: sales forecast ($m), 2008-14 98 Table 35: Boehringer Ingelheim's R&D pipeline (Phase I-registration) 100 Table 36: Exchange rates, 2009 103 List of Figures Figure 1: The PharmaVitae Explorer 3
Successful lifecycle management is expected to help Flomax and Sifrol continue to contribute strong sales in spite of patent loss and increased competition, thus avoiding the same fate as Mobic.
Internationally, it is marketed by Boehringer Ingelheim and Pharmacia as MIRAPEX, MIRAPEXIN or SIFROL.